ProCE Banner Activity

NeoTrio: Neoadjuvant Pembrolizumab Alone, Combined With, or in Sequence With Dabrafenib and Trametinib in Resectable BRAFV600-Mutant Stage III Melanoma

Slideset Download
Conference Coverage
Concurrent neoadjuvant dabrafenib and trametinib and pembrolizumab resulted in high pathologic response rate in patients with stage III melanoma, although with increased toxicity compared with sequential regimen or pembrolizumab monotherapy.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab